MRNA vs WDC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 06, 2026

MRNA

48.8
AI Score
VS
WDC Wins

WDC

54.9
AI Score

Investment Advisor Scores

MRNA

49score
Recommendation
HOLD

WDC

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA WDC Winner
Revenue 534.00M 9.17B WDC
Net Income -2.13B 6.23B WDC
Net Margin -397.9% 67.9% WDC
Operating Income -2.20B 2.89B WDC
ROE -31.4% 64.3% WDC
ROA -19.4% 41.4% WDC
Total Assets 10.96B 15.04B WDC
Cash 1.72B 2.05B WDC
Debt/Equity 0.09 0.16 MRNA
Current Ratio 2.29 1.49 MRNA
Free Cash Flow -1.25B 2.23B WDC

Relative Price Performance (Last 90 Days)

MRNA 1M: -22.7% · 3M: +21.9% WDC 1M: -24.9% · 3M: -6.4%

Current Technical Phase

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.2 · Price: $59.17

WDC

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 38.4 · Price: $434.30

Fundamentals Snapshot

Metric MRNA WDC
Market Cap
Forward P/E -11.0 23.7
Trailing P/E 18.6
Revenue (TTM)
Revenue Growth 0.0% 0.5%
Gross Margin -0.7% 0.5%
Operating Margin -5.6% 0.4%
EPS -7.88 24.30
Dividend Yield 0.00%

Frequently Asked Questions

Based on our detailed analysis, WDC is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.